Optimizing the treatment of NLPHL for every adult and child.

The Global nLPHL One Working Group (GLOW) is an international, multidisciplinary collaborative research group that aims to improve the diagnosis and treatment of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). 


We serve as a coordinated research hub to drive NLPHL discovery across the age continuum.

2024 GLOW Summit


Event Details

Date:             October 25, 2024

Location:    Cologne, Germany

Time:            16:30 CEST (German time)

Length:        Approx. 4 hours


Dinner will be provided.  

Why study NLPHL?

NLPHL is distinct from other Hodgkin lymphomas.

NLPHL is highly treatable, but its slow-growing nature and its likelihood of late relapse(s) and risk of transformation to more aggressive types of lymphoma over 20 years after initial diagnosis distinguish it from classic Hodgkin lymphoma (cHL).

There is no standard of care for the treatment of NLPHL.

Historically, NLPHL has been categorized as a subtype of Hodgkin lymphoma and treated in the same manner as classic Hodgkin lymphoma, despite the clinically significant differences between these two entities.

No formal evaluation of patients' values, preferences, and priorities has been conducted in regards to NLPHL treatment.

There are many factors patients weigh when making NLPHL treatment decisions. Researchers lack information about patients' priorities and preferences, and patients and clinicians lack historical data and resources to make fully informed treatment decisions. The scarcity of long-term outcomes data (both clinical and patient-reported) makes it difficult to learn from past patients’ experiences.

No frontline Hodgkin lymphoma trial anywhere in the world currently includes patients with NLPHL.

Unlike cHL, NLPHL does not typically express the CD30 marker. When researchers began using the antibody-drug conjugate brentuximab vedotin, which targets CD30-positive cells, in Hodgkin lymphoma clinical trials the early 2000s, patients with NLPHL were excluded from frontline Hodgkin lymphoma clinical trials. Because of this, no additional data is being collected to establish a standard of care for these patients.

There is uncertainty regarding how to best classify NLPHL.

Debates about how to classify NLPHL have continued since subtypes of Hodgkin lymphoma were first identified. NLPHL was not recognized as a distinct entity by the WHO until 1997, and researchers are currently divided between whether to classify NLPHL as a type of Hodgkin lymphoma or of non-Hodgkin lymphoma. To better understand NLPHL, researchers need a centralized NLPHL tissue bank for further analyses.

Scientific understanding of NLPHL lags behind more common cancers.

NLPHL is rare. It comprises only 5-10% of Hodgkin lymphoma cases, which makes it challenging to study due to fewer patients, data, and biospecimens available for research. Retrospective NLPHL data that do exist were collected in various ways at different institutions in numerous countries, posing challenges to aggregating sufficient numbers of cases for meaningful discovery.

Many current gaps in knowledge about NLPHL and optimal treatment strategies can be addressed via global collaboration.

Research groups investigating NLPHL have been largely fragmented by age group (pediatric versus adult clinicians) and by region. Coordinating research efforts and streamlining prospective data dictionaries and biospecimen acquisition facilitates the pooling of larger data sets and biospecimen samples for higher-powered research.

What makes GLOW different from prior NLPHL research efforts?

We are learning from past research and experience, so we:

Get Involved!